(Q35824515)

10 August 2017

1 reference

title

Cyclophosphamide: new approaches for systemic lupus erythematosus (English)

1 reference

systemic lupus erythematosus

10 August 2017

main subject

0 references

1

M Petri

1 reference

10 August 2017

publication date

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

13

1 reference

10 August 2017

issue

5

1 reference

10 August 2017

page(s)

366-371

1 reference

Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

Treatment of lupus nephritis: a meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

Use of testosterone to prevent cyclophosphamide-induced azoospermia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

BK virus (BKV) quantification in urine samples of bone marrow transplanted patients is helpful for diagnosis of hemorrhagic cystitis, although wide individual variations exist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

4-Hydroperoxycyclophosphamide inhibits proliferation by human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

High-dose cyclophosphamide for severe systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

Autologous haematopoietic stem cell transplants for autoimmune disease--feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1028OA

10.1191/0961203303LU1028OA

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference